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In September 2005, the 3rd International 
Workshop for the Study of Itch was held 
in Heidelberg, Germany.* The larg-
est meeting of its kind, the Workshop 
had in attendance 200 scientists and 
physicians interested in itch from 
throughout the world. The meeting was 
organized by Elke Weisshaar (University 
of Heidelberg, Germany), with the help 
of fellow Germans Martin Schmelz, 
Sonja Ständer, and Thomas Mettang. 
The Workshop covered a variety of 
topics relevant to itch, such as recent 
neurophysiological aspects, interesting 
forms of localized and systemic itch, 
current human and animal itch models, 
and psychosocial aspects of itch. The 
key topics addressed at the Workshop 
are reported here.
Weisshaar opened the conference by 
presenting a historical overview of the 
symptom of itch, starting at the first writ-
ten records of the symptom, descrip-
tions in the writings of Hippocrates on 
cases of pruritus vulvae, prurigo, and 
senile pruritus. Weisshaar then followed 
itch through European history, from the 
first definition of the symptom, pro-
posed by Samuel Hafenreffer in 1660 
as an unpleasant desire to scratch, to 
records of infectious itch in the Middle 
Ages and, finally, the relationship of 
itch to pruritic diseases in nineteenth-
century Europe.
Even though it has long been an 
interest of European physicians and is 
today one of the most common der-
matological complaints, there is only 
minimal published information about 
the epidemiology of this debilitating 
symptom in the general population. F. 
Dalgard (University of Oslo, Norway) 
presented her investigation of the 
prevalence of pruritus in a large survey 
in Oslo focused on quality of life and 
skin complaints. The method used was 
a questionnaire on self-reported skin 
complaints. Of the 40,888 question-
naires sent by mail to adult subjects in 
the city of Oslo, 18,770 were returned. 
The prevalence of itch in this general 
population was 7.5% among men 
and 9.2% among women. Individuals 
who had experienced more negative 
life events and depression, according 
to Dalgard and colleagues, reported 
more itch; social support systems were 
found to be a protective factor for 
reporting itch.
Several speakers covered the 
field of uremic pruritus. B. Wikström 
(University of Uppsala, Sweden) report-
ed on the prevalence of itch in hemodi-
alysis patients, based on data from the 
Dialysis Outcomes and Practice Patterns 
Study, a large multinational study cov-
ering populations in the United States, 
Europe, Australia, and Japan. The preva-
lence rate of itch among the more than 
12,000 hemodialysis patients was 47%. 
In addition, the itch reported by the 
patients was correlated with a lower 
quality of life. Wikström reported that 
patients with itch (as compared with 
patients without itch) were significantly 
more likely to be male and also had 
higher mortality rates.
T. Mettang, Department of 
Nephrology, German Clinic for 
Diagnostics, Wiesbaden, Germany) 
described three factors involved in 
the pathogenesis of uremic pruritus: 
uremic xerosis, uremic neuropathy, and 
uremia-related microinflammation. The 
hypothesis that uremic neuropathy 
could be a cause of uremic pruritus 
led to the introduction of gabapentin 
as a treatment option. Mettang report-
ed that gabapentin showed surpris-
ing effectiveness in the treatment of 
this symptom. In contrast, µ-receptor 
antagonists such as naltrexone have 
been used in uremic pruritus with 
conflicting results. According to the 
hypothesis that an imbalance of µ- and 
κ-opioid receptors may trigger uremic 
pruritus, one study examined whether 
the κ-receptor agonist TRK-820 leads 
to relief of the symptom. The prelimi-
nary results of this study appeared to 
be encouraging. In addition, UVB 
irradiation continues to be the most 
commonly and successfully used ther-
apeutic strategy. G. Yosipovitch (Wake 
Forest University School of Medicine, 
Winston-Salem, NC) presented data of 
the prevalence of uremic pruritus in a 
large hemodialysis center in the United 
States. The overall prevalence rate in 
this center was 57%. A positive correla-
tion was noted between itch and serum 
calcium concentrations, as well as itch 
and higher Kt/V, which is a measure of 
dialysis efficacy. Uremic itch adversely 
impacted several aspects of quality of 
life in the studied population.
Factors related to itch in cholestasis 
were reviewed by N. Bergasa (State 
University of New York at Downstate, 
Brooklyn). Bergasa presented pre-
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liminary data on a single-nucleotide 
polymorphism in multidrug resistance-
associated protein 2 (MRP2), which 
is expressed on the bile canalicular 
membrane in patients with primary 
biliary cirrhosis (an autoimmune liver 
disease) and which can cause intract-
able itch. Patients with mutations of 
MRP2 had significantly more itch than 
patients without these mutations. This 
is the first report of a possible genetic 
link for susceptibility of itch and may 
open the field for both studying mole-
cular markers of itch and developing 
new animal models and specific treat-
ments for itch. Bergasa also reviewed 
several treatment modalities for chole-
static itch and mentioned that opiate 
antagonists are specific antipruritics for 
cholestatic itch, as supported by data 
from controlled trials. The κ-agonist 
and µ-antagonist inhaler butorphanol 
seems to be effective for some patients 
resistant to opiate antagonist treat-
ments and has minimal abuse poten-
tial. Neuropathic pain medications 
such as gabapentin, however, do not 
seem to be as effective for the treat-
ment of cholestatic itch.
J. Szepietowski (University of 
Wroclaw, Poland) presented data on 
stigmatization, depression levels, and 
itch in psoriatic patients. In patients 
with psoriasis, the stigmatization level 
significantly correlated with pruritus 
severity as measured by several ques-
tionnaires, including the Dermatology 
Life Quality Index and the Beck 
Depression Inventory. Moreover, a sig-
nificant correlation was noted between 
pruritus intensity, quality of life, depres-
sion level, and stress severity, assessed 
by the Holmes-Rahe scale and by self-
assessment scale. Many of the psoriatic 
patients felt stigmatized by the disease. 
The presented study clearly indicates 
the significant influence of itching on 
patients’ well-being, including feeling 
of stigmatization level.
Several new therapeutic ven-
ues for treatments were reviewed by 
S. Ständer (University of Münster, 
Germany). Among the most promising 
new therapies are those involving the 
direct influence of cutaneous neurore-
ceptors by their agonists. For example, 
the transient receptor potential (TRP) 
family is expressed on sensory nerve 
fibers. This explains why capsaicin is 
effective in treatment of localized itch. 
Ständer presented data demonstrating 
that the topical immunomodulators 
tacrolimus and pimecrolimus bind to 
TRPV receptors in skin nerves; this may 
explain both their initial side effect of 
burning and their rapid effect on itch. 
Other members of the TRP family that 
are activated by cold (TRPM8) may 
be involved in modulation of itch. 
Ständer also discussed current usages 
of cannabinoid receptor agonists in the 
treatment of itch. Both cannabinoid 
2 and cannabinoid 1 receptors were 
found on skin nerves and mast cells. 
Upon local application, these recep-
tors were found to have antipruritic 
effects in patients. This topic was later 
elaborated by R. Rukwied (University 
of Mannheim, Germany). Rukwied’s 
group showed that locally applied can-
nabinoid agonists reduce experimen-
tally induced itch and allodynia. This is 
explained by the activation of periph-
erally expressed cannabinoid receptors 
that evoke secondary mediator release 
due to activation of vanilloid and opio-
id receptors.
The mechanism of the effect of pho-
totherapy in relieving itch as well as 
the effect of light in inducing itch was 
thoroughly described by J. Wallengren 
(University of Lund, Sweden). UV radi-
ation sensitizes keratinocytes and skin 
nociceptors, leading to a secretion of 
substance P and calcitonin gene-related 
peptide. The effect of sun exposure in 
inducing itch in localized neuropathic 
itch, according to Wallengren, is due to 
photodamage of nociceptors.
Numerous new findings of the neu-
robiology of pruritus in the skin, spi-
nal cord, and brain were also present-
ed by A. Ikoma (University of Kyoto, 
Japan) and M. Schmelz (University of 
Mannheim, Germany). Both inves-
tigators presented new findings on 
electrically evoked itch in humans. 
Their results suggest the existence 
of novel C-fibers that induce itch in 
a different way than the histamine-
sensitive itch C-fibers that Schmelz 
found more than eight years ago. In 
addition, M. Ringkamp (Johns Hopkins 
University, Baltimore, MD) presented 
data on a new class of itch neurons. 
Electrophysiological recordings of 
these neurons from primary afferents 
in monkeys reveal that mechano-
heat-sensitive C-fiber afferents are 
activated by active cowhage spicules 
to mediate pruritus. This suggests 
that these fibers may play an impor-
tant role in histamine-independent 
itch. Another topic was a new in vitro 
tri-compartment model for the co-cul-
turing of neurons, glial cells, and epi-
dermal cells, for studies of itch and 
effective therapies, which was pre-
sented by L. Misery (University of Brest, 
France). By using confocal scanner laser 
microscopy, Misery found the presence 
of synapse-like connections between 
nerve endings and epidermal cells.
Several researchers presented stud-
ies on the brain imaging of itch using 
functional magnetic resonance imag-
ing and positron emission tomography. 
A fascinating talk on brain mecha-
nisms involved in itch was presented 
by F. McGlone (University of Wales, 
Bangor, UK). McGlone presented a 
series of movies that showed how the 
expressions of people scratching can 
be a model of emotional communi-
cation among humans. Several inde-
pendent lines of evidence suggest that 
these expressions are very similar in 
related primate species. This elabo-
rate communication is accompanied 
by specialization of brain areas in 
the premotor cortex and is based on 
the recent discovery of “mirror neu-
rons,” which are located in the pre-
frontal cortex and respond to actions 
performed by an individual but also 
when that individual watches the 
same action performed by others. This 
could explain some of the cognitive 
factors involved in itch and the com-
mon event of contagious scratching. 
E. Carstens (University of California, 
Davis) reported on current findings of 
the neuronal pathway in animals. For 
example, intradermal injection of low-
potency pruritics such as serotonin 
in humans elicits significant bouts of 
hindlimb scratching directed toward 
the injection site. The frequency and 
duration of scratch bouts are constant, 
but the number of bouts increases with 
concentration and is decreased by 
opioid antagonists, suggesting that itch 
activates a central pattern generator 
governing the scratch reflex.
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The Workshop’s best-poster award 
was presented to T. Andoh and Y. Kuraishi 
(Toyama Medical and Pharmaceutical 
University, Japan) for “Hydroxyl radical 
is involved in substance P-induced itch-
associated responses in mice.” In their 
study, the authors investigated how oxi-
dative stress is involved in the induction 
of itch. The authors showed that itch 
induced by an intradermal injection 
of substance P could be inhibited by a 
simultaneous intradermal injection of 
antioxidants (sodium salicylate, N-acetyl 
cysteine, and Trolox) in a dose-depend-
ent manner. Moreover, they showed that 
the application of substance P induced 
the production of hydroxyl radical in 
primary cultures of mouse keratino-
cytes. In addition, hydrogen peroxide 
increased intracellular Ca2+ ion con-
centration in primary cultures of mouse 
dorsal root ganglion neurons. These 
results suggest that hydrogen peroxide 
is an itch mediator produced by kerati-
nocytes and that hydrogen peroxide is 
involved in substance P-induced itch-
associated response.
The Workshop ended with a lively 
discussion of a proposed classification 
of pruritus. The increase in knowledge 
of pruritus during the last few years had 
encouraged the discussion on a classi-
fication of pruritus that would enable 
clinicians to provide diagnostic and 
therapeutic algorithms based on one 
shared lexicon. Several suggestions 
for classifications were discussed, but 
no definite conclusion was reached. 
The panel, which included J. Bernhard 
(University of Massachusetts, Worcester, 
MA), M. Schmelz, S. Ständer, and 
G. Yosipovitch, did come to a con-
clusion, however, that a clinical clas-
sification would be more proper than 
classifications that are neurophysi-
ological in nature.
Finally, this year’s Workshop was 
the location for the official launch of 
the International Forum for the Study 
of Itch (IFSI), the first international 
society that exclusively focuses on 
itch research. The IFSI is a multidis-
ciplinary international association for 
clinical practitioners, researchers, and 
scientists dedicated to improving the 
understanding and treatment of itch 
for the benefit of suffering patients 
worldwide. The main mission of the 
organization is to advance itch-related 
research and education and to pro-
mote treatment and clinical efforts to 
help alleviate this debilitating symp-
tom. In addition to managing all 
future Workshops for the Study of Itch, 
the IFSI will also disseminate new 
information about itch to its members, 
the international medical commu-
nity, and the public at large through 
various media.
The next meeting of the International 
Workshop for the Study of Itch is sche-
duled to take place in San Francisco, 
California, USA, in September 2007 
and will be organized by E. Carstens. 
For more information about the IFSI 
or future meetings, visit us online at 
http://www.itchforum.org.
*The 3rd International Workshop for the Study 
of Itch was held at the Heidelberg Marriott 
Hotel in Heidelberg, Germany, 25–27 
September 2005.
